Dassault Systèmes did not wait for the “metaverse” fashion to take an interest in virtual worlds. Since its founding in 1991, the French software publisher has offered its customers the tools to model in 3D the products they plan to design and simulate their life cycle. Known for its solutions in the automotive, aerospace and industrial sectors, the French company is less known for its activity in a field that it has nevertheless been exploring for about ten years: that of the living.
On the occasion of the Consumer Electronics Show (CES) in Las Vegas, the world’s largest trade fair for technological innovation, which was held from January 5 to 7, she presented, for the first time to the general public, the result of a long work of seven years which allowed him to realize the digital double of a human heart. Reproduction is not only formal, it integrates knowledge about the functioning of the organ: how the muscles and fibers in the heart act, how the electric current circulates there, what are the known reactions to drugs, etc.
To achieve this result, several hundred scientists, practitioners and healthcare industry around the world shared their expertise on a common platform. From this base of knowledge, Dassault Systèmes first recreated a healthy heart in digital form, then made possible the ability to deform it at will to faithfully model patients’ hearts. For the moment, it takes a day to carry out this operation, but this duration is set to be reduced to a handful of minutes in the coming years.
There are many opportunities for the solution: preparing operations, tailor-made implants, but also performing clinical trials using a database of patients whose hearts have already been duplicated in the virtual world.
An infinite field of possibilities
“When we embarked on this adventure, nobody, apart from us, really believed in it, testifies Doctor Steven Levine, who piloted the project. Today, it has been proven that the product is ready and, in the future, not a single clinical test will be performed on patients without prior virtual testing ”, continues the scientist by stressing that the initiative benefits from the support of the Food and Drug Administration), which manages, in the United States, all the authorizations of marketing of drugs. Companies such as Abbott or Phillips are already using the product.
You have 28.67% of this article to read. The rest is for subscribers only.